Technology | April 02, 2014

Acist Launches RXi Rapid Exchange FFR System

System allows quick and easy assessment of FFR values with ultra-thin Navvus MicroCatheter that can be used over standard 0.014-inch guidewires

Acist RXi Rapid Exchange FFR System April 2014 ACC.14

April 2, 2014 — Acist Medical Systems Inc. announced at the American College of Cardiology's 63rd Annual Scientific Session in Washington, D.C., the global introduction of the new Acist|RXi Rapid Exchange FFR system — the world's first rapid exchange FFR system. This device features new technology designed to provide physicians with a fast and easy way to perform fractional flow reserve (FFR) procedures.

The new Rapid FFR system utilizes the ultra-thin Acist Navvus Rapid Exchange MicroCatheter and RXi console. The Navvus MicroCatheter can be used over a standard 0.014-inch guidewire, providing the physician maximum control while maintaining wire position throughout the coronary procedure. The RXi system also facilitates rapid FFR assessments before, during and post-intervention, to quickly assess blockages that could require percutaneous coronary intervention (PCI). This technology is the first of its kind, providing the reassurance of accurate and reliable FFR measurements and the advantages of rapid exchange platform.

FFR is a fast-growing market within interventional cardiology. With the stent market facing scrutiny about placement and usage, FFR procedures are growing in popularity worldwide. To meet this growing demand, Acist has created technology that takes a unique approach from the existing wire-based technologies. In addition to being a Rapid Exchange catheter, the Acist Rapid FFR system utilizes fiber-optic technology, resulting in greater signal stability and less potential for signal drift. The ultra-thin Navvus MicroCatheter features simple plug and play by not requiring calibration therefore saving time and increasing ease of use versus older FFR wire-base systems.

RXi received 510(k) Food and Drug Administration (FDA) clearance for use in obtaining intravascular pressure measurements in the diagnosis and treatment of coronary and peripheral artery disease in January 2014. The company successfully conducted a clinical trial in New Zealand and is currently performing an additional study in Europe. The first successful human case featuring the new system in the United States took place in Minnesota in February 2014. The new technology continues to draw praise from participating physicians citing the new device's simple and intuitive approach.

The Acist|RXi Rapid Exchange FFR System is one of the most exciting developments in interventional cardiology in the last five years," said Dr. Antonio Colombo of the Centro Cuore Columbus, Milan, Italy, who has conducted live case demonstrations at TCT.13, JIM,and CRT 2014 interventional cardiology conferences. "By allowing the use of standard guidewires to deliver the fiber-optic driven pressure sensor, the RXi may simplify FFR measurement allowing it to be used routinely for detection of ischemia-related lesions when objective evidence of vessel-related ischemia is not available."

For more information: www.acist.com

Related Content

Among high-risk, chronic, coronary patients who undergo angioplasty, there were no additional benefits from ticagrelor compared to the current standard of care clopidogrel. #AHA #AHA20 #AHA2020
News | Cath Lab | November 16, 2020
November 16, 2020 — The use of the more potent antiplatelet medication ticagrelor (Brilinta) was not superior to clop
A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect
Feature | Cath Lab | October 18, 2020
October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benef
A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin capped fibrous atheroma (TCFA). #TCTconnect #TCT2020

A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin cap fibro-atheroma (TCFA).

News | Cath Lab | October 18, 2020
October 18, 2020 – Data from the...
The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions. #TCT2-0

The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions.

Feature | Cath Lab | October 16, 2020
October 15, 2020 — Shockwave Medical's Intravascular Lithotripsy (IVL) system to treat severely calcified coronary ar
Videos | Cath Lab | October 16, 2020
This is an example pf the Shockwave Medical Intravascular Lithotripsy (IVL) catheter system designed to break up heav
Videos | Cath Lab | July 15, 2020
Richard Botto, CVT, RCSA, chief cardiovascular technologist, division of cardiology, cardiac cath lab, offers an over
Videos | Cath Lab | July 13, 2020
The Vieussens’ arterial ring (VAR) is a connection between the conus artery and the left anterior descending (LAD) co
News | Cath Lab | July 06, 2020
July 6, 2020 — Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major